董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steven Rubin | 男 | Independent Director | 59 | 37.88万美元 | 未持股 | 2020-04-20 |
| Roger Kornberg | 男 | Director | 72 | 未披露 | 未持股 | 2020-04-20 |
| Gary Wilcox | 男 | Director, Chairman and Chief Executive Officer | 73 | 20.10万美元 | 未持股 | 2020-04-20 |
| Anthony Japour | 男 | Independent Director | 60 | 未披露 | 未持股 | 2020-04-20 |
| Phillip Frost | 男 | Independent Director | 83 | 36.83万美元 | 未持股 | 2020-04-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James Martin | 男 | Chief Financial Officer | 53 | 23.10万美元 | 未持股 | 2020-04-20 |
| Gary Wilcox | 男 | Director, Chairman and Chief Executive Officer | 73 | 20.10万美元 | 未持股 | 2020-04-20 |
| Sam Lee | 男 | President | 61 | 24.10万美元 | 未持股 | 2020-04-20 |
董事简历
中英对照 | 中文 | 英文- Steven Rubin
-
Steven Rubin，2007年5月起，担任OPKO Health, Inc.的行政执行副总裁；2007年2月起，担任董事。2001年8月至2006年9月，他担任IVAX的高级副总裁、法律总顾问、秘书。他现为下列公司的董事：Tiger Media, Inc.， （NYSE MKT：IDI）， 中国的多平台广告牌和广告公司；Cocrystal Pharma, Inc.，该公司采用独特的核苷化学方法开发 新型抗病毒疗法，以治疗严重和/或慢性病毒疾病；Non-Invasive Monitoring Systems, Inc. （OTCBB：NIMU），医疗器械公司；Sevion Therapeutics, Inc.， 从事新型替代产品的研究、开发、收购，以治疗癌症、免疫疾病；Tiger X Medical, Inc. （OTCBB：CDOM）， 原是一个早期阶段的骨科医疗器械公司，专门从事设计、开发和销售重建联合装置及脊柱外科设备； Castle Brands, Inc. （NYSE MKT：ROX）， 高档品牌酒类的开发销售商。他曾担任下列公司的董事：Dreams, Inc.，（ （NYSE MKT： DRJ）），垂直整合的体育授权及产品公司；Safestitch Medical, Inc.， 医疗器械公司 （OTCQB：SFES）， 后来被TransEnterix, Inc.收购；PROLOR Biotech, Inc. ，后来与 OKPO合并。2008年7月1日，当选为本公司董事。他是美国佛罗里达州的居民，还是本公司的审计、治理、提名委员会的成员。
Steven Rubin has been a director of Cocrystal since January 2 2014 and a director of Cocrystal Discovery since 2008. Mr. Rubin has been the Executive Vice President of OPKO, since May 2007 and a director of OPKO since February 2007. In addition to OPKO, Mr. Rubin currently serves on the board of directors of Red Violet, Inc. NASDAQ CM:RDVT, a software and services company, Non-Invasive Monitoring Systems, Inc. (OTC US:NIMU), a medical device company, Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical stage biopharmaceutical company dedicated to treating patients suffering from rare and ultra-rare disease caused by premature termination codon nonsense mutations, Neovasc, Inc. (NASDAQ CM:NVCN), a company that develops and markets medical specialty vascular devices, and ChromaDex Corp. (NASDAQ CM:CDXC), a science-based, integrated nutraceutical company devoted to improving the way people age. Mr. Rubin previously served as a director of VBI Vaccines, Inc. (NASDAQ CM:VBIV), a biopharmaceutical company developing next generation vaccines, BioCardia, Inc.(NASDAQ GS: BCDA), a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases, Cogint, Inc. (NASDAQ GM:COGT), now known as Fluent, Inc. (NASDAQ:FLNT), an information solutions provider focused on the data-fusion market, prior to the spin-off of its data and analytics operations and assets into Red Violet, Inc., Kidville, Inc. (OTCBB:KVIL), which operates large, upscale facilities, catering to newborns through five-year-old children and their families and offers a wide range of developmental classes for newborns to five-year-olds, Sevion Therapeutics, Inc., prior to its merger with Eloxx Pharmaceuticals, Inc., Dreams, Inc. (NYSE American:DRJ), a vertically integrated sports licensing and products company, SciVac Therapeutics, Inc. prior to its merger with VBI Vaccines, Inc., Tiger X Medical, Inc. prior to its merger with BioCardia, Inc., and Castle Brands, Inc. (NYSE American:ROX), a developer and marketer of premium brand spirits. Mr. Rubin also served as the Senior Vice President, General Counsel and Secretary of IVAX from August 2001 until September 2006. - Steven Rubin，2007年5月起，担任OPKO Health, Inc.的行政执行副总裁；2007年2月起，担任董事。2001年8月至2006年9月，他担任IVAX的高级副总裁、法律总顾问、秘书。他现为下列公司的董事：Tiger Media, Inc.， （NYSE MKT：IDI）， 中国的多平台广告牌和广告公司；Cocrystal Pharma, Inc.，该公司采用独特的核苷化学方法开发 新型抗病毒疗法，以治疗严重和/或慢性病毒疾病；Non-Invasive Monitoring Systems, Inc. （OTCBB：NIMU），医疗器械公司；Sevion Therapeutics, Inc.， 从事新型替代产品的研究、开发、收购，以治疗癌症、免疫疾病；Tiger X Medical, Inc. （OTCBB：CDOM）， 原是一个早期阶段的骨科医疗器械公司，专门从事设计、开发和销售重建联合装置及脊柱外科设备； Castle Brands, Inc. （NYSE MKT：ROX）， 高档品牌酒类的开发销售商。他曾担任下列公司的董事：Dreams, Inc.，（ （NYSE MKT： DRJ）），垂直整合的体育授权及产品公司；Safestitch Medical, Inc.， 医疗器械公司 （OTCQB：SFES）， 后来被TransEnterix, Inc.收购；PROLOR Biotech, Inc. ，后来与 OKPO合并。2008年7月1日，当选为本公司董事。他是美国佛罗里达州的居民，还是本公司的审计、治理、提名委员会的成员。
- Steven Rubin has been a director of Cocrystal since January 2 2014 and a director of Cocrystal Discovery since 2008. Mr. Rubin has been the Executive Vice President of OPKO, since May 2007 and a director of OPKO since February 2007. In addition to OPKO, Mr. Rubin currently serves on the board of directors of Red Violet, Inc. NASDAQ CM:RDVT, a software and services company, Non-Invasive Monitoring Systems, Inc. (OTC US:NIMU), a medical device company, Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical stage biopharmaceutical company dedicated to treating patients suffering from rare and ultra-rare disease caused by premature termination codon nonsense mutations, Neovasc, Inc. (NASDAQ CM:NVCN), a company that develops and markets medical specialty vascular devices, and ChromaDex Corp. (NASDAQ CM:CDXC), a science-based, integrated nutraceutical company devoted to improving the way people age. Mr. Rubin previously served as a director of VBI Vaccines, Inc. (NASDAQ CM:VBIV), a biopharmaceutical company developing next generation vaccines, BioCardia, Inc.(NASDAQ GS: BCDA), a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases, Cogint, Inc. (NASDAQ GM:COGT), now known as Fluent, Inc. (NASDAQ:FLNT), an information solutions provider focused on the data-fusion market, prior to the spin-off of its data and analytics operations and assets into Red Violet, Inc., Kidville, Inc. (OTCBB:KVIL), which operates large, upscale facilities, catering to newborns through five-year-old children and their families and offers a wide range of developmental classes for newborns to five-year-olds, Sevion Therapeutics, Inc., prior to its merger with Eloxx Pharmaceuticals, Inc., Dreams, Inc. (NYSE American:DRJ), a vertically integrated sports licensing and products company, SciVac Therapeutics, Inc. prior to its merger with VBI Vaccines, Inc., Tiger X Medical, Inc. prior to its merger with BioCardia, Inc., and Castle Brands, Inc. (NYSE American:ROX), a developer and marketer of premium brand spirits. Mr. Rubin also served as the Senior Vice President, General Counsel and Secretary of IVAX from August 2001 until September 2006.
- Roger Kornberg
-
Roger Kornberg自2016年2月起担任公司董事。Kornberg是U.S. National Academy of Sciences成员；Stanford University结构生物学专业医学Winzer教授。他于1967年获得Harvard University化学学士学位；1972年获得Stanford化学物理学博士学位。他是英国坎布里奇Laboratory of Molecular Biology博士后研究员；1976年成为Harvard Medical School生物化学助理教授；1978年成为Stanford Medical School结构生物学教授。2006年Kornberg被授予诺贝尔化学奖，因其对真核基因转录（DNA被复制到RNA的过程）微生物的研究而获此殊荣。Kornberg还是多个奖项的获得者，包括2001年Welch Prize（美国化学领域最高奖项）；2002年Leopald Mayer Prize（法官生物医疗科学领域最高奖项）。
Roger Kornberg,has served as a member of Xenetic Biosciences, Inc. Board since February 2016. Dr. Kornberg is a member of the U.S. National Academy of Sciences and the Winzer Professor of Medicine in the Department of Structural Biology at Stanford University. He earned his B.S. in chemistry from Harvard University in 1967 and his Ph.D. in chemical physics from Stanford in 1972. He became a postdoctoral fellow at the Laboratory of Molecular Biology in Cambridge, England and then an assistant professor of biological chemistry at Harvard Medical School in 1976, before moving to his present position as professor of structural biology at Stanford Medical School in 1978. In 2006, Dr. Kornberg was awarded the Nobel Prize in Chemistry in recognition for his studies of the molecular basis of Eukaryotic Transcription, the process by which DNA is copied to RNA. Dr. Kornberg is also the recipient of several awards, including the 2001 Welch Prize, the highest award granted in the field of chemistry in the United States, and the 2002 Leopald Mayer Prize, the highest award granted in the field of biomedical sciences from the French Academy of Sciences. Dr. Kornberg has served as a director of Cocrystal Pharma, Inc. (NasdaqCM: COCP) since April 2020. - Roger Kornberg自2016年2月起担任公司董事。Kornberg是U.S. National Academy of Sciences成员；Stanford University结构生物学专业医学Winzer教授。他于1967年获得Harvard University化学学士学位；1972年获得Stanford化学物理学博士学位。他是英国坎布里奇Laboratory of Molecular Biology博士后研究员；1976年成为Harvard Medical School生物化学助理教授；1978年成为Stanford Medical School结构生物学教授。2006年Kornberg被授予诺贝尔化学奖，因其对真核基因转录（DNA被复制到RNA的过程）微生物的研究而获此殊荣。Kornberg还是多个奖项的获得者，包括2001年Welch Prize（美国化学领域最高奖项）；2002年Leopald Mayer Prize（法官生物医疗科学领域最高奖项）。
- Roger Kornberg,has served as a member of Xenetic Biosciences, Inc. Board since February 2016. Dr. Kornberg is a member of the U.S. National Academy of Sciences and the Winzer Professor of Medicine in the Department of Structural Biology at Stanford University. He earned his B.S. in chemistry from Harvard University in 1967 and his Ph.D. in chemical physics from Stanford in 1972. He became a postdoctoral fellow at the Laboratory of Molecular Biology in Cambridge, England and then an assistant professor of biological chemistry at Harvard Medical School in 1976, before moving to his present position as professor of structural biology at Stanford Medical School in 1978. In 2006, Dr. Kornberg was awarded the Nobel Prize in Chemistry in recognition for his studies of the molecular basis of Eukaryotic Transcription, the process by which DNA is copied to RNA. Dr. Kornberg is also the recipient of several awards, including the 2001 Welch Prize, the highest award granted in the field of chemistry in the United States, and the 2002 Leopald Mayer Prize, the highest award granted in the field of biomedical sciences from the French Academy of Sciences. Dr. Kornberg has served as a director of Cocrystal Pharma, Inc. (NasdaqCM: COCP) since April 2020.
- Gary Wilcox
-
Gary Wilcox自2014年1月2日起担任Cocrystal董事，自2016年7月22日起担任首席执行官。Wilcox博士自2020年2月1日起担任董事长。从2014年1月2日到2015年3月11日，Wilcox博士从2014年11月25日开始担任CoCrystal的董事会联合主席兼首席执行官。他是CoCrystal Discovery的联合创始人，并于2008年至2015年3月担任其首席执行官。自2012年以来，Wilcox博士一直担任Daily Journal Corporation（Nasdaq:DJCO）的董事，该公司是一家合法报纸和网站的出版商，也是法律案件管理软件的开发商。从1993年到2007年，Wilcox博士担任ICOS Corporation（纳斯达克市场代码:ICOS）的运营执行Vice President和董事会成员，他在CIALIS的开发中发挥了关键作用，CIALIS是一种年销售额为20亿美元的药物。1982年，Wilcox博士共同创立了Ingene Inc.（纳斯达克市场代码:IGEI），通过私人融资、首次公开募股和1989年与XOMA Corporation（纳斯达克市场代码:XOMA）成功合并，担任其董事长、总裁兼首席执行官。从1989年到1993年，Wilcox博士担任XOMA的董事和执行Vice President的Vice Chairman of the Board。从1974年到1984年，Wilcox博士是加州大学洛杉矶分校（UCLA）的微生物学教授和分子生物学研究所成员。他曾任职15个董事会，包括纳斯达克、纽约和伦敦证券交易所公司以及私人技术公司。
Gary Wilcox has been a director of Cocrystal since January 2 2014 and has served as the Chief Executive Officer since July 22 2016. Dr. Wilcox has served as Chairman since February 1 2020. From January 2 2014 until March 11 2015 Dr. Wilcox served as the Chairman of the Board Co-Chairman beginning November 25 2014 and Chief Executive Officer of Cocrystal. He is a co-founder of Cocrystal Discovery and served as its Chief Executive Officer from 2008 through March 2015. Since 2012 Dr. Wilcox has been a director of the Daily Journal Corporation (Nasdaq:DJCO), a publisher of legal newspapers and websites, and a developer of legal case management software. From 1993 to 2007 Dr. Wilcox served as Executive Vice President of Operations and a member of the Board of Directors of Icos Corporation (Nasdaq:ICOS), where he played a key role in the development of Cialis, a drug with annual sales of $2 billion. In 1982 Dr. Wilcox co-founded Ingene Inc. (Nasdaq:IGEI), serving as its Chairman, President and CEO through private financings, an IPO and a successful merger with XOMA Corporation (Nasdaq:XOMA) in 1989. From 1989-1993 Dr. Wilcox was Vice Chairman of the Board of Directors and Executive Vice President of Xoma. From 1974 until 1984 Dr. Wilcox was a Professor of Microbiology and a member of the Molecular Biology Institute at UCLA. He has served on 15 boards of directors including Nasdaq, New York and London stock exchange companies as well as private technology companies. - Gary Wilcox自2014年1月2日起担任Cocrystal董事，自2016年7月22日起担任首席执行官。Wilcox博士自2020年2月1日起担任董事长。从2014年1月2日到2015年3月11日，Wilcox博士从2014年11月25日开始担任CoCrystal的董事会联合主席兼首席执行官。他是CoCrystal Discovery的联合创始人，并于2008年至2015年3月担任其首席执行官。自2012年以来，Wilcox博士一直担任Daily Journal Corporation（Nasdaq:DJCO）的董事，该公司是一家合法报纸和网站的出版商，也是法律案件管理软件的开发商。从1993年到2007年，Wilcox博士担任ICOS Corporation（纳斯达克市场代码:ICOS）的运营执行Vice President和董事会成员，他在CIALIS的开发中发挥了关键作用，CIALIS是一种年销售额为20亿美元的药物。1982年，Wilcox博士共同创立了Ingene Inc.（纳斯达克市场代码:IGEI），通过私人融资、首次公开募股和1989年与XOMA Corporation（纳斯达克市场代码:XOMA）成功合并，担任其董事长、总裁兼首席执行官。从1989年到1993年，Wilcox博士担任XOMA的董事和执行Vice President的Vice Chairman of the Board。从1974年到1984年，Wilcox博士是加州大学洛杉矶分校（UCLA）的微生物学教授和分子生物学研究所成员。他曾任职15个董事会，包括纳斯达克、纽约和伦敦证券交易所公司以及私人技术公司。
- Gary Wilcox has been a director of Cocrystal since January 2 2014 and has served as the Chief Executive Officer since July 22 2016. Dr. Wilcox has served as Chairman since February 1 2020. From January 2 2014 until March 11 2015 Dr. Wilcox served as the Chairman of the Board Co-Chairman beginning November 25 2014 and Chief Executive Officer of Cocrystal. He is a co-founder of Cocrystal Discovery and served as its Chief Executive Officer from 2008 through March 2015. Since 2012 Dr. Wilcox has been a director of the Daily Journal Corporation (Nasdaq:DJCO), a publisher of legal newspapers and websites, and a developer of legal case management software. From 1993 to 2007 Dr. Wilcox served as Executive Vice President of Operations and a member of the Board of Directors of Icos Corporation (Nasdaq:ICOS), where he played a key role in the development of Cialis, a drug with annual sales of $2 billion. In 1982 Dr. Wilcox co-founded Ingene Inc. (Nasdaq:IGEI), serving as its Chairman, President and CEO through private financings, an IPO and a successful merger with XOMA Corporation (Nasdaq:XOMA) in 1989. From 1989-1993 Dr. Wilcox was Vice Chairman of the Board of Directors and Executive Vice President of Xoma. From 1974 until 1984 Dr. Wilcox was a Professor of Microbiology and a member of the Molecular Biology Institute at UCLA. He has served on 15 boards of directors including Nasdaq, New York and London stock exchange companies as well as private technology companies.
- Anthony Japour
-
Anthony Japour在过去的25年里一直担任生物技术和制药高管，拥有尽职调查经验，并在初创公司和成熟的生物制药公司的成长阶段拥有建立创业型组织的人才。Japour的职业生涯始于医学博士，在哈佛医学院接受传染病的亚专业培训；他晋升为医学助理教授，并被授予著名的美国艾滋病基金会学者奖，随后是NIH-NIAID K-11医师科学家奖和NIH RO1。从1996年到2002年，Japour在雅培公司NYSE:ABT从事制药行业的抗病毒药物开发，他在该公司担任Kaletra®；的I-III阶段开发团队的领导团队成员，该公司是一家针对HIV感染的重磅药物以及其他HIV药物组合。在Gilead Sciences（纳斯达克交易代码:GILD）收购Triangle Pharmaceuticals之前，Japour代表雅培对Triangle Pharmaceuticals的抗病毒产品组合进行了尽职调查。后来，Japour在市场上的产品开发中监管了多个治疗领域，包括HIV，移植，疼痛和RSV。2002年和2019年，Japour被他的同事推荐担任食品和药物管理局局长。多年来，日本一直为许多制药和生物技术公司提供咨询，并一直是其思想领袖，为政府和非政府实体提供咨询，并与许多合同研究实验室密切合作，其中包括两家上市的CRO，他最近从2016年到2020年在PPD和ICON全职工作。Japour目前在Cocrystal Pharma, Inc.（纳斯达克市场代码:COCP）的董事会任职，此前曾在Opko 医疗保健（纳斯达克市场代码:OPK）的董事会任职。Japour目前也是iToLerance的首席执行官，最近担任美国AdvanceDDX生物实验室的首席执行官。一家下一代测序公司。他拥有密歇根大学安娜堡分校的学士学位和西北大学医学院的医学博士学位。
Anthony Japour,has been a biotech and pharmaceutical executive for the last 25 years with due diligence experience and a talent for building entrepreneurial organizations in startup and established biopharmaceutical companies through the growth phase. Japour began his career as an MD, trained at Harvard Medical School with subspecialty training in Infectious Diseases; he rose to the rank of Assistant Professor of Medicine, and was awarded the prestigious American Foundation for AIDS Scholar award, followed by a NIH-NIAID K-11 Physician Scientist Award and NIH RO1. From 1996 to 2002 Japour moved to the pharmaceutical industry at Abbott Laboratories NYSE: ABT in antiviral drug development where he was on the leadership team for the Phase I-III development team for KALETRA®, a blockbuster drug for HIV infection as well as other HIV drug combinations. Japour performed due diligence of the Triangle Pharmaceuticals antiviral portfolio on behalf of Abbott and prior to the Gilead Sciences (Nasdaq: GILD) acquisition of Triangle Pharmaceuticals. Later, Japour oversaw multiple therapeutic areas including HIV, Transplant, Pain, and RSV in Marketed Product Development. In 2002 and 2019 Japour was recommended by his colleagues to be nominated to serve as Commissioner of the Food and Drug Administration. Over the years, Japour has consulted and been a thought leader for many pharmaceutical and biotechnology companies, advising governmental and non-governmental entities and has worked closely with numerous Contract Research Laboratories including two publicly held CROs, PPD (Nasdaq: PPDI) and ICON (Nasdaq: ICLR) where he recently worked full-time from 2016 to 2020. Japour currently serves on the board of Cocrystal Pharma, Inc., (Nasdaq: COCP) and previously served on the board of Opko Healthcare (Nasdaq: OPK). Japour is also currently CEO of iTolerance, and recently served as CEO of AdvancedDx Biological Laboratories, USA. a Next Generation Sequencing company. He holds a B.S from the University of Michigan, Ann Arbor and M.D. from Northwestern University Medical School. - Anthony Japour在过去的25年里一直担任生物技术和制药高管，拥有尽职调查经验，并在初创公司和成熟的生物制药公司的成长阶段拥有建立创业型组织的人才。Japour的职业生涯始于医学博士，在哈佛医学院接受传染病的亚专业培训；他晋升为医学助理教授，并被授予著名的美国艾滋病基金会学者奖，随后是NIH-NIAID K-11医师科学家奖和NIH RO1。从1996年到2002年，Japour在雅培公司NYSE:ABT从事制药行业的抗病毒药物开发，他在该公司担任Kaletra®；的I-III阶段开发团队的领导团队成员，该公司是一家针对HIV感染的重磅药物以及其他HIV药物组合。在Gilead Sciences（纳斯达克交易代码:GILD）收购Triangle Pharmaceuticals之前，Japour代表雅培对Triangle Pharmaceuticals的抗病毒产品组合进行了尽职调查。后来，Japour在市场上的产品开发中监管了多个治疗领域，包括HIV，移植，疼痛和RSV。2002年和2019年，Japour被他的同事推荐担任食品和药物管理局局长。多年来，日本一直为许多制药和生物技术公司提供咨询，并一直是其思想领袖，为政府和非政府实体提供咨询，并与许多合同研究实验室密切合作，其中包括两家上市的CRO，他最近从2016年到2020年在PPD和ICON全职工作。Japour目前在Cocrystal Pharma, Inc.（纳斯达克市场代码:COCP）的董事会任职，此前曾在Opko 医疗保健（纳斯达克市场代码:OPK）的董事会任职。Japour目前也是iToLerance的首席执行官，最近担任美国AdvanceDDX生物实验室的首席执行官。一家下一代测序公司。他拥有密歇根大学安娜堡分校的学士学位和西北大学医学院的医学博士学位。
- Anthony Japour,has been a biotech and pharmaceutical executive for the last 25 years with due diligence experience and a talent for building entrepreneurial organizations in startup and established biopharmaceutical companies through the growth phase. Japour began his career as an MD, trained at Harvard Medical School with subspecialty training in Infectious Diseases; he rose to the rank of Assistant Professor of Medicine, and was awarded the prestigious American Foundation for AIDS Scholar award, followed by a NIH-NIAID K-11 Physician Scientist Award and NIH RO1. From 1996 to 2002 Japour moved to the pharmaceutical industry at Abbott Laboratories NYSE: ABT in antiviral drug development where he was on the leadership team for the Phase I-III development team for KALETRA®, a blockbuster drug for HIV infection as well as other HIV drug combinations. Japour performed due diligence of the Triangle Pharmaceuticals antiviral portfolio on behalf of Abbott and prior to the Gilead Sciences (Nasdaq: GILD) acquisition of Triangle Pharmaceuticals. Later, Japour oversaw multiple therapeutic areas including HIV, Transplant, Pain, and RSV in Marketed Product Development. In 2002 and 2019 Japour was recommended by his colleagues to be nominated to serve as Commissioner of the Food and Drug Administration. Over the years, Japour has consulted and been a thought leader for many pharmaceutical and biotechnology companies, advising governmental and non-governmental entities and has worked closely with numerous Contract Research Laboratories including two publicly held CROs, PPD (Nasdaq: PPDI) and ICON (Nasdaq: ICLR) where he recently worked full-time from 2016 to 2020. Japour currently serves on the board of Cocrystal Pharma, Inc., (Nasdaq: COCP) and previously served on the board of Opko Healthcare (Nasdaq: OPK). Japour is also currently CEO of iTolerance, and recently served as CEO of AdvancedDx Biological Laboratories, USA. a Next Generation Sequencing company. He holds a B.S from the University of Michigan, Ann Arbor and M.D. from Northwestern University Medical School.
- Phillip Frost
-
Phillip Frost，医学博士， 2007年3月以来担任Ladenburg Thalmann Financial Services Inc.公司的CEO和董事会主席。2010年3月，他被任命为Teva Pharmaceutical Industries, Limited, or Teva NYSE：TEVA董事会主席，2006年1月Teva 被IVAX Corporation收购时，他曾担任董事会副主席。他于1987年曾任IVAX公司董事会主席兼首席执行官。1972年至1986年，他担任位于迈阿密的美国西奈山医学中心皮肤科（the Department of Dermatology at Mt. Sinai Medical Center of Greater Miami）主任。他于1972年是Key Pharmaceuticals, Inc.董事会主席，直至该公司在1986年被Schering Plough Corporation收购。他于2006年7月被任命为Ladenburg Thalmann Financial Services Inc. （NYSE MKT：LTS）董事会主席，LTS是一家投资银行、资产管理、证券经纪公司，通过其主要的运营子公司Ladenburg Thalmann & Co . Inc 。 而提供服务。2001年到2002年、以及2004年至今，他是Ladenburg Thalmann董事会成员。他担任迈阿密大学（the University of Miami）理事会、俄罗斯the Skolkovo-Scientific Advisory Council顾问委会、中国上海先进免疫化学研究所（the Shanghai Institute for Advanced Immunochemical Studies in China）、佛罗里达受托委员会（The Florida Council）100名成员之一，并是the Miami Jewish Home for the Aged和西奈山医疗中心（the Mount Sinai Medical Center）理事会成员。他也是高档品牌开发和营销商Castle Brands （NYSE MKT：ROX）董事、开发抗病毒治疗人类疾病的生物科技公司Biozone Pharmaceuticals Inc. （OTCBB： BZNE）、发展阶段医疗设备公司TransEnterix,Inc 。（OTCBB：TRXC）（TRXC开创性的使用灵活的仪器和机器人提高微创手术）等公司的董事。他之前于2013年8月担任Continucare Corporation公司、SafeStitch Medical Inc.公司（并入TransEnterix, Inc.公司之前）、PROLOR Biotech, Inc.公司（被Cocrystal Pharma, Inc.收购之前）的董事，于2012年12月担任美国证交所（现在的纽约证交所MKT）主管人员和联席副主席，并直至2012年11月担任the Scripps Research Institute理事会成员。他已成功建立一些制药公司，并监管大量医药产品的发展和商业化。
Phillip Frost,has been the Chief Executive Officer of the Company and Chairman of the Board since March 2007. Dr. Frost serves as a director for Cocrystal Pharma, Inc. (NASDAQ GM:COCP), a biotechnology company developing new treatments for viral diseases. He also currently serves on the board of Grove Bank & Trust and Morgan Solar. He has been a member of the Board of Trustees of the University of Miami since 1983 and was Chairman from 2001 to 2004. He is on the Advisory Board of the Shanghai Institute for Advanced Immunochemical Studies in China, is a member of The Florida Council of 100 and is a trustee of the Miami Jewish Home for the Aged and serves on the Executive Committee of the Board of Mount Sinai Medical Center. He serves as Chairman of Temple Emanu-El, Governor of Tel Aviv University and is a member of the Executive Committee of The Phillip and Patricia Frost Museum of Science. Dr. Frost served as a director of Ladenburg Thalmann Financial Services Inc. from 2004 to 2006 and as Chairman from July 2006 until September 2018. Dr. Frost previously served as a director for Castle Brands (NYSE American:ROX). Dr. Frost had served as Chairman of the Board of Directors and Chief Executive Officer of IVAX Corporation ("IVAX") from 1987 until its acquisition by Teva in January 2006. Dr. Frost was Chairman of the Board of Directors of Key Pharmaceuticals, Inc. from 1972 until its acquisition by Schering Plough Corporation in 1986. Dr. Frost was a Governor of the American Stock Exchange from 1992 to 2008 and Co-Vice Chairman from 2001 until its merger with the New York Stock Exchange. - Phillip Frost，医学博士， 2007年3月以来担任Ladenburg Thalmann Financial Services Inc.公司的CEO和董事会主席。2010年3月，他被任命为Teva Pharmaceutical Industries, Limited, or Teva NYSE：TEVA董事会主席，2006年1月Teva 被IVAX Corporation收购时，他曾担任董事会副主席。他于1987年曾任IVAX公司董事会主席兼首席执行官。1972年至1986年，他担任位于迈阿密的美国西奈山医学中心皮肤科（the Department of Dermatology at Mt. Sinai Medical Center of Greater Miami）主任。他于1972年是Key Pharmaceuticals, Inc.董事会主席，直至该公司在1986年被Schering Plough Corporation收购。他于2006年7月被任命为Ladenburg Thalmann Financial Services Inc. （NYSE MKT：LTS）董事会主席，LTS是一家投资银行、资产管理、证券经纪公司，通过其主要的运营子公司Ladenburg Thalmann & Co . Inc 。 而提供服务。2001年到2002年、以及2004年至今，他是Ladenburg Thalmann董事会成员。他担任迈阿密大学（the University of Miami）理事会、俄罗斯the Skolkovo-Scientific Advisory Council顾问委会、中国上海先进免疫化学研究所（the Shanghai Institute for Advanced Immunochemical Studies in China）、佛罗里达受托委员会（The Florida Council）100名成员之一，并是the Miami Jewish Home for the Aged和西奈山医疗中心（the Mount Sinai Medical Center）理事会成员。他也是高档品牌开发和营销商Castle Brands （NYSE MKT：ROX）董事、开发抗病毒治疗人类疾病的生物科技公司Biozone Pharmaceuticals Inc. （OTCBB： BZNE）、发展阶段医疗设备公司TransEnterix,Inc 。（OTCBB：TRXC）（TRXC开创性的使用灵活的仪器和机器人提高微创手术）等公司的董事。他之前于2013年8月担任Continucare Corporation公司、SafeStitch Medical Inc.公司（并入TransEnterix, Inc.公司之前）、PROLOR Biotech, Inc.公司（被Cocrystal Pharma, Inc.收购之前）的董事，于2012年12月担任美国证交所（现在的纽约证交所MKT）主管人员和联席副主席，并直至2012年11月担任the Scripps Research Institute理事会成员。他已成功建立一些制药公司，并监管大量医药产品的发展和商业化。
- Phillip Frost,has been the Chief Executive Officer of the Company and Chairman of the Board since March 2007. Dr. Frost serves as a director for Cocrystal Pharma, Inc. (NASDAQ GM:COCP), a biotechnology company developing new treatments for viral diseases. He also currently serves on the board of Grove Bank & Trust and Morgan Solar. He has been a member of the Board of Trustees of the University of Miami since 1983 and was Chairman from 2001 to 2004. He is on the Advisory Board of the Shanghai Institute for Advanced Immunochemical Studies in China, is a member of The Florida Council of 100 and is a trustee of the Miami Jewish Home for the Aged and serves on the Executive Committee of the Board of Mount Sinai Medical Center. He serves as Chairman of Temple Emanu-El, Governor of Tel Aviv University and is a member of the Executive Committee of The Phillip and Patricia Frost Museum of Science. Dr. Frost served as a director of Ladenburg Thalmann Financial Services Inc. from 2004 to 2006 and as Chairman from July 2006 until September 2018. Dr. Frost previously served as a director for Castle Brands (NYSE American:ROX). Dr. Frost had served as Chairman of the Board of Directors and Chief Executive Officer of IVAX Corporation ("IVAX") from 1987 until its acquisition by Teva in January 2006. Dr. Frost was Chairman of the Board of Directors of Key Pharmaceuticals, Inc. from 1972 until its acquisition by Schering Plough Corporation in 1986. Dr. Frost was a Governor of the American Stock Exchange from 1992 to 2008 and Co-Vice Chairman from 2001 until its merger with the New York Stock Exchange.
高管简历
中英对照 | 中文 | 英文- James Martin
James Martin，2015年3月4日以来，他一直担任首席财务官。此前，他曾担任Vaporin公司的首席财务官（2014年4月以来）。担任Vaporin公司的首席财务官之前，他曾担任Non-Invasive Monitoring Systems公司（NIMS，上市医疗器械公司）的首席财务官（2011年1月以来）。他此前曾担任SafeStitch Medical公司（上市医疗器械公司）的首席财务官（从2011年1月到2013年10月）。从2011年1月到2011年12月，他曾担任Aero Pharmaceuticals公司（私营医药经销商，于2011年12月自愿解散）的财务副总裁。从2010年7月到2011年1月，他曾担任NIMS公司、SafeStitch公司、Aero公司的总会计师。从2008年5月到2010年7月，他曾担任AAR Aircraft Services-Miami公司（ AAR Corp的子公司，一个航空航天和国防公司）的总会计师，在那里他负责所有的财务报表和库存物流。
James Martin has served as our Chief Financial Officer since June 1 2017. Prior to that, from February 23 2017 through May 30 2017 Mr. Martin served as our Interim Chief Financial Officer. Mr. Martin has also served as Chief Financial Officer of Non-Invasive Monitoring Systems, Inc. OTC:NIMU since January 2011. From November 2016 to February 2017 Mr. Martin served as Chief Financial Officer of Motus GI Holdings, Inc., a privately held medical device company. From September 2014 to November 2016 Mr. Martin served as Chief Financial Officer of VBI Vaccines Inc. (formerly SciVac Therapeutics, Inc.) (Nasdaq:VBIV), a pharmaceutical development and manufacturing company. From April 2014 to September 2015 Mr. Martin served as Chief Financial Officer of Vapor Corp, Inc. (Nasdaq:VPCO), a vaporizer retail and wholesale company. From January 2011 to October 2013 Mr. Martin served as Chief Financial Officer of SafeStitch prior to its merger with TransEnterix, Inc (NYSE:TRXC).- James Martin，2015年3月4日以来，他一直担任首席财务官。此前，他曾担任Vaporin公司的首席财务官（2014年4月以来）。担任Vaporin公司的首席财务官之前，他曾担任Non-Invasive Monitoring Systems公司（NIMS，上市医疗器械公司）的首席财务官（2011年1月以来）。他此前曾担任SafeStitch Medical公司（上市医疗器械公司）的首席财务官（从2011年1月到2013年10月）。从2011年1月到2011年12月，他曾担任Aero Pharmaceuticals公司（私营医药经销商，于2011年12月自愿解散）的财务副总裁。从2010年7月到2011年1月，他曾担任NIMS公司、SafeStitch公司、Aero公司的总会计师。从2008年5月到2010年7月，他曾担任AAR Aircraft Services-Miami公司（ AAR Corp的子公司，一个航空航天和国防公司）的总会计师，在那里他负责所有的财务报表和库存物流。
- James Martin has served as our Chief Financial Officer since June 1 2017. Prior to that, from February 23 2017 through May 30 2017 Mr. Martin served as our Interim Chief Financial Officer. Mr. Martin has also served as Chief Financial Officer of Non-Invasive Monitoring Systems, Inc. OTC:NIMU since January 2011. From November 2016 to February 2017 Mr. Martin served as Chief Financial Officer of Motus GI Holdings, Inc., a privately held medical device company. From September 2014 to November 2016 Mr. Martin served as Chief Financial Officer of VBI Vaccines Inc. (formerly SciVac Therapeutics, Inc.) (Nasdaq:VBIV), a pharmaceutical development and manufacturing company. From April 2014 to September 2015 Mr. Martin served as Chief Financial Officer of Vapor Corp, Inc. (Nasdaq:VPCO), a vaporizer retail and wholesale company. From January 2011 to October 2013 Mr. Martin served as Chief Financial Officer of SafeStitch prior to its merger with TransEnterix, Inc (NYSE:TRXC).
- Gary Wilcox
Gary Wilcox自2014年1月2日起担任Cocrystal董事，自2016年7月22日起担任首席执行官。Wilcox博士自2020年2月1日起担任董事长。从2014年1月2日到2015年3月11日，Wilcox博士从2014年11月25日开始担任CoCrystal的董事会联合主席兼首席执行官。他是CoCrystal Discovery的联合创始人，并于2008年至2015年3月担任其首席执行官。自2012年以来，Wilcox博士一直担任Daily Journal Corporation（Nasdaq:DJCO）的董事，该公司是一家合法报纸和网站的出版商，也是法律案件管理软件的开发商。从1993年到2007年，Wilcox博士担任ICOS Corporation（纳斯达克市场代码:ICOS）的运营执行Vice President和董事会成员，他在CIALIS的开发中发挥了关键作用，CIALIS是一种年销售额为20亿美元的药物。1982年，Wilcox博士共同创立了Ingene Inc.（纳斯达克市场代码:IGEI），通过私人融资、首次公开募股和1989年与XOMA Corporation（纳斯达克市场代码:XOMA）成功合并，担任其董事长、总裁兼首席执行官。从1989年到1993年，Wilcox博士担任XOMA的董事和执行Vice President的Vice Chairman of the Board。从1974年到1984年，Wilcox博士是加州大学洛杉矶分校（UCLA）的微生物学教授和分子生物学研究所成员。他曾任职15个董事会，包括纳斯达克、纽约和伦敦证券交易所公司以及私人技术公司。
Gary Wilcox has been a director of Cocrystal since January 2 2014 and has served as the Chief Executive Officer since July 22 2016. Dr. Wilcox has served as Chairman since February 1 2020. From January 2 2014 until March 11 2015 Dr. Wilcox served as the Chairman of the Board Co-Chairman beginning November 25 2014 and Chief Executive Officer of Cocrystal. He is a co-founder of Cocrystal Discovery and served as its Chief Executive Officer from 2008 through March 2015. Since 2012 Dr. Wilcox has been a director of the Daily Journal Corporation (Nasdaq:DJCO), a publisher of legal newspapers and websites, and a developer of legal case management software. From 1993 to 2007 Dr. Wilcox served as Executive Vice President of Operations and a member of the Board of Directors of Icos Corporation (Nasdaq:ICOS), where he played a key role in the development of Cialis, a drug with annual sales of $2 billion. In 1982 Dr. Wilcox co-founded Ingene Inc. (Nasdaq:IGEI), serving as its Chairman, President and CEO through private financings, an IPO and a successful merger with XOMA Corporation (Nasdaq:XOMA) in 1989. From 1989-1993 Dr. Wilcox was Vice Chairman of the Board of Directors and Executive Vice President of Xoma. From 1974 until 1984 Dr. Wilcox was a Professor of Microbiology and a member of the Molecular Biology Institute at UCLA. He has served on 15 boards of directors including Nasdaq, New York and London stock exchange companies as well as private technology companies.- Gary Wilcox自2014年1月2日起担任Cocrystal董事，自2016年7月22日起担任首席执行官。Wilcox博士自2020年2月1日起担任董事长。从2014年1月2日到2015年3月11日，Wilcox博士从2014年11月25日开始担任CoCrystal的董事会联合主席兼首席执行官。他是CoCrystal Discovery的联合创始人，并于2008年至2015年3月担任其首席执行官。自2012年以来，Wilcox博士一直担任Daily Journal Corporation（Nasdaq:DJCO）的董事，该公司是一家合法报纸和网站的出版商，也是法律案件管理软件的开发商。从1993年到2007年，Wilcox博士担任ICOS Corporation（纳斯达克市场代码:ICOS）的运营执行Vice President和董事会成员，他在CIALIS的开发中发挥了关键作用，CIALIS是一种年销售额为20亿美元的药物。1982年，Wilcox博士共同创立了Ingene Inc.（纳斯达克市场代码:IGEI），通过私人融资、首次公开募股和1989年与XOMA Corporation（纳斯达克市场代码:XOMA）成功合并，担任其董事长、总裁兼首席执行官。从1989年到1993年，Wilcox博士担任XOMA的董事和执行Vice President的Vice Chairman of the Board。从1974年到1984年，Wilcox博士是加州大学洛杉矶分校（UCLA）的微生物学教授和分子生物学研究所成员。他曾任职15个董事会，包括纳斯达克、纽约和伦敦证券交易所公司以及私人技术公司。
- Gary Wilcox has been a director of Cocrystal since January 2 2014 and has served as the Chief Executive Officer since July 22 2016. Dr. Wilcox has served as Chairman since February 1 2020. From January 2 2014 until March 11 2015 Dr. Wilcox served as the Chairman of the Board Co-Chairman beginning November 25 2014 and Chief Executive Officer of Cocrystal. He is a co-founder of Cocrystal Discovery and served as its Chief Executive Officer from 2008 through March 2015. Since 2012 Dr. Wilcox has been a director of the Daily Journal Corporation (Nasdaq:DJCO), a publisher of legal newspapers and websites, and a developer of legal case management software. From 1993 to 2007 Dr. Wilcox served as Executive Vice President of Operations and a member of the Board of Directors of Icos Corporation (Nasdaq:ICOS), where he played a key role in the development of Cialis, a drug with annual sales of $2 billion. In 1982 Dr. Wilcox co-founded Ingene Inc. (Nasdaq:IGEI), serving as its Chairman, President and CEO through private financings, an IPO and a successful merger with XOMA Corporation (Nasdaq:XOMA) in 1989. From 1989-1993 Dr. Wilcox was Vice Chairman of the Board of Directors and Executive Vice President of Xoma. From 1974 until 1984 Dr. Wilcox was a Professor of Microbiology and a member of the Molecular Biology Institute at UCLA. He has served on 15 boards of directors including Nasdaq, New York and London stock exchange companies as well as private technology companies.
- Sam Lee
Sam Lee自2014年1月2日起担任我们的总裁。从2014年1月2日到2014年11月22日，Lee博士担任CoCrystal的董事。他是CoCrystal Discovery公司的联席创始人，并自2007年以来一直担任CoCrystal Discovery公司的总裁兼董事。他拥有超过25年的抗感染药物发现研究经验。担任CoCrystal的联合创始人之前，他在ICOS Corporation管理抗感染、肿瘤学和炎症药物发现项目8年。Lee博士负责将蛋白质晶体学和结构生物学方法纳入ICOS研究。他在圣母大学（University of Notre Dame）获得生物科学博士学位，并在斯坦福大学（Stanford University）与I.R.Lehman博士一起完成病毒复制生物化学博士后培训。在斯坦福大学（Stanford）时，Lee博士在加利福尼亚州库比蒂诺（Cupertino）创立并担任病毒检测首席执行官。
Sam Lee has served as our President since January 2 2014. From January 2 2014 to November 22 2014 Dr. Lee was a director of Cocrystal. He is a co-founder of Cocrystal Discovery and has been President and a director of Cocrystal Discovery since 2007. He has over 25 years of anti-infective drug discovery research experience. Prior to being a co-founder of Cocrystal, he managed anti-infective, oncology, and inflammation drug discovery projects for eight years at ICOS Corporation. Dr. Lee was responsible for incorporating protein crystallography and structural biology approaches into ICOS research. He received his Ph.D. in Biological Sciences from the University of Notre Dame, and completed postdoctoral training in viral replication biochemistry with Dr. I. R. Lehman at Stanford University. While at Stanford, Dr. Lee founded and was Chief Executive Officer of Viral Assays in Cupertino, CA.- Sam Lee自2014年1月2日起担任我们的总裁。从2014年1月2日到2014年11月22日，Lee博士担任CoCrystal的董事。他是CoCrystal Discovery公司的联席创始人，并自2007年以来一直担任CoCrystal Discovery公司的总裁兼董事。他拥有超过25年的抗感染药物发现研究经验。担任CoCrystal的联合创始人之前，他在ICOS Corporation管理抗感染、肿瘤学和炎症药物发现项目8年。Lee博士负责将蛋白质晶体学和结构生物学方法纳入ICOS研究。他在圣母大学（University of Notre Dame）获得生物科学博士学位，并在斯坦福大学（Stanford University）与I.R.Lehman博士一起完成病毒复制生物化学博士后培训。在斯坦福大学（Stanford）时，Lee博士在加利福尼亚州库比蒂诺（Cupertino）创立并担任病毒检测首席执行官。
- Sam Lee has served as our President since January 2 2014. From January 2 2014 to November 22 2014 Dr. Lee was a director of Cocrystal. He is a co-founder of Cocrystal Discovery and has been President and a director of Cocrystal Discovery since 2007. He has over 25 years of anti-infective drug discovery research experience. Prior to being a co-founder of Cocrystal, he managed anti-infective, oncology, and inflammation drug discovery projects for eight years at ICOS Corporation. Dr. Lee was responsible for incorporating protein crystallography and structural biology approaches into ICOS research. He received his Ph.D. in Biological Sciences from the University of Notre Dame, and completed postdoctoral training in viral replication biochemistry with Dr. I. R. Lehman at Stanford University. While at Stanford, Dr. Lee founded and was Chief Executive Officer of Viral Assays in Cupertino, CA.